Back to Search
MATTHEW KEATING, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1275948481IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A139205(CA)
Education
UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Class of 2014
Research & Publications (20)
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.
PMID 19074592·J Mol Diagn·2009
8-other
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies.
PMID 16201050·Clin Adv Hematol Oncol·2005
8-other
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
PMID 15767648·J Clin Oncol·2005
3-trial
Genetic approaches to disease and regeneration.
PMID 15293807·Philos Trans R Soc Lond B Biol Sci·2004
6-review
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.
PMID 15072613·Clin Lymphoma·2004
8-other
Biology and treatment of chronic lymphocytic leukemia.
PMID 14633781·Hematology Am Soc Hematol Educ Program·2003
6-review
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
PMID 11986207·Blood·2002
3-trial
Management of chronic lymphocytic leukemia: a changing field.
PMID 12823777·Rev Clin Exp Hematol·2002
6-review
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
PMID 12685828·Leuk Lymphoma·2002
8-other
Identification of a key residue in the conformational stability of acyl carrier protein.
PMID 12445484·Biochim Biophys Acta·2002
4-observational
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
PMID 11842391·Semin Oncol·2002
6-review
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
PMID 11773171·J Clin Oncol·2002
4-observational
Progress in CLL, chemotherapy, antibodies and transplantation.
PMID 11769960·Biomed Pharmacother·2001
8-other
Chronic lymphocytic leukemia . Clinical oral poster session.
PMID 11036949·Hematol Cell Ther·2000
6-review
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
PMID 10721771·Leuk Lymphoma·2000
8-other
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
PMID 19646755·Leuk Res·2010
3-trial
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
PMID 18190591·Int J Lab Hematol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 101 The City Dr S
Orange, CA 92868 - Phone
- (714) 612-1192
Quick Facts
- NPI
- 1275948481
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 3
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile